Department of Clinical Biochemistry, Kashmar School of Nursing, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Pharm Des. 2023;29(10):766-776. doi: 10.2174/1381612829666230306123455.
Non-coding RNAs (ncRNAs) are emerging as important regulators in various pathological conditions, including human cancers. NcRNAs exert potentially crucial effects on cell cycle progression, proliferation, and invasion in cancer cells by targeting various cell cycle-related proteins at transcriptional and post-transcriptional levels. As one of the key cell cycle regulatory proteins, p21 is involved in various processes, including the cellular response to DNA damage, cell growth, invasion, metastasis, apoptosis, and senescence. P21 has been shown to have either a tumor-suppressive or oncogenic effect depending on the cellular localization and posttranslational modifications. P21 exerts a significant regulatory effect on both G1/S and G2/M checkpoints by regulating the function of cyclin-dependent kinase enzymes (CDKs) or interacting with proliferating cell nuclear antigen (PCNA). P21 has an important effect on the cellular response to DNA damage by separating DNA replication enzymes from PCNA and inhibiting DNA synthesis resulting in G1 phase arrest. Furthermore, p21 has been shown to negatively regulate the G2/M checkpoint through the inactivation of cyclin-CDK complexes. In response to any cell damage caused by genotoxic agents, p21 exerts its regulatory effects by nuclear preservation of cyclin B1-CDK1 and preventing their activation. Notably, several ncRNAs, including lncRNAs and miRNAs, have been shown to be involved in tumor initiation and progression through the regulation of the p21 signaling axis. In this review, we discuss the miRNA/lncRNA-dependent mechanisms that regulate p21 and their effects on gastrointestinal tumorigenesis. A better understanding of the regulatory effects of ncRNAs on the p21 signaling may help to discover novel therapeutic targets in gastrointestinal cancer.
非编码 RNA(ncRNA)在各种病理条件下(包括人类癌症)作为重要的调节剂而出现。ncRNA 通过在转录和转录后水平靶向各种细胞周期相关蛋白,对癌细胞的细胞周期进程、增殖和侵袭产生潜在的关键影响。作为关键的细胞周期调节蛋白之一,p21 参与各种过程,包括细胞对 DNA 损伤的反应、细胞生长、侵袭、转移、凋亡和衰老。p21 的作用取决于细胞定位和翻译后修饰,可以是肿瘤抑制因子,也可以是癌基因。p21 通过调节细胞周期依赖性激酶(CDK)酶的功能或与增殖细胞核抗原(PCNA)相互作用,对 G1/S 和 G2/M 检查点产生显著的调节作用。p21 通过将 DNA 复制酶与 PCNA 分离并抑制 DNA 合成,从而导致 G1 期停滞,对细胞对 DNA 损伤的反应产生重要影响。此外,p21 通过使细胞周期蛋白-CDK 复合物失活来负调控 G2/M 检查点。当受到遗传毒性药物引起的任何细胞损伤时,p21 通过核保留细胞周期蛋白 B1-CDK1 并阻止其激活来发挥其调节作用。值得注意的是,包括长非编码 RNA(lncRNA)和 microRNA(miRNA)在内的几种 ncRNA 已被证明通过调节 p21 信号轴参与肿瘤的发生和发展。在这篇综述中,我们讨论了调节 p21 的 miRNA/lncRNA 依赖性机制及其对胃肠道肿瘤发生的影响。更好地理解 ncRNA 对 p21 信号的调节作用可能有助于发现胃肠道癌的新治疗靶点。